Ohio State Genomic Health will launch later in 2024 and enroll 100,000 participants to participate in genetic screening for more than four years. The program will be optional and provided at no cost to participants, according to a July 23 news release from OSU Wexner Medical Center.
Helix’s technology will be used to screen participants’ genetic information for variants associated with breast and ovarian cancer, colorectal cancer and high cholesterol, the release said.
“This partnership will expand and accelerate research across Ohio State focused on understanding mechanisms underlying human disease as well as development of diagnostics and treatments for patients. This is a critical platform for prevention and treatment,” Peter Mohler, PhD, executive vice president for research, innovation and knowledge at the university and chief scientific officer at OSU Wexner Medical Center, said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
